Butterfly Network, Inc. (BFLY) is a medical device company that makes handheld ultrasound systems using proprietary ultrasound-on-chip semiconductor technology. Its flagship point-of-care ultrasound (POCUS) devices aim to make imaging more portable and affordable for clinicians. In recent quarters, the company has expanded beyond hardware into software and platform offerings, including its Butterfly Embedded program and the Butterfly Garden artificial intelligence (AI) marketplace.
The $11 price level matters because it sits just above the stock's 52-week high of $10.05 and matches the most bullish analyst price target currently published. It also represents a psychological milestone roughly 15% above recent trading levels near $9.50, making it a meaningful but not far-fetched objective for investors evaluating the stock's next move.
The stock has staged a dramatic recovery from its 52-week low of $1.34, reflecting a broader shift in sentiment toward the company's platform transition and improving fundamentals. Butterfly Network reported record second-quarter revenue of approximately $32.6 million and raised its full-year 2026 revenue outlook to a range of roughly $119 million to $123 million. Analysts now expect continued double-digit revenue growth into 2027.
Wall Street's consensus rating is "Strong Buy," with an average 12-month price target near $9.31 to $10.50 depending on the data provider. Individual targets range widely, from around $5.25 on the low end to $11 on the high end, underscoring genuine disagreement about how quickly the business can scale and reach profitability.
Several catalysts could support a move toward $11. The company's co-development and licensing agreement with Midjourney brought in a $15 million upfront fee plus an annual license fee, creating a new software-like revenue stream. Management has also highlighted Butterfly Embedded, which embeds its imaging technology into third-party devices, and the Butterfly Garden ecosystem, where partner developers can launch FDA-cleared AI applications.
Additionally, Butterfly Network has pursued government opportunities through FedRAMP certification, which could unlock procurement eligibility across federal agencies such as the Department of Veterans Affairs. Its Home & Community Care initiative, which moves ultrasound into at-home monitoring for conditions like congestive heart failure, represents a potential long-term growth avenue. Continued revenue beats, progress toward profitability, or successful commercialization of these newer segments could give the stock the fundamental support needed to approach $11.
The most significant obstacle remains profitability. Butterfly Network still reports net losses and negative earnings per share, with elevated research and development spending weighing on the bottom line. Because the company trades largely on future growth expectations rather than current earnings, any slowdown in revenue growth, delay in enterprise deals, or miss relative to guidance could pressure the valuation.
Valuation also presents a challenge. Some independent analyses suggest the stock trades modestly above estimated fair value, implying that much of the optimistic scenario may already be reflected in the price. The wide dispersion in analyst targets reflects this uncertainty: several firms hold targets of $6 or less, well below the $11 objective.
From a technical analysis perspective, the $10.05 area is the key resistance level. It marks the stock's previous major high, and a decisive break above it would be required before the $11 target becomes realistically in play. On the downside, the psychological $9 level and the broader $8 range have served as areas where buyers previously stepped in. A sustained hold above $9 would help preserve the stock's longer-term recovery trend, while a failure to defend that zone could signal fading momentum.
Traders monitoring Butterfly Network and thousands of other stocks and ETFs can turn to Tickeron's AI Daily Buy/Sell Signals. The product uses artificial intelligence to continuously evaluate changing market conditions, technical behavior, and AI-driven analysis, then generates Buy, Sell, or Hold signals designed to help users spot emerging opportunities, track existing positions, and identify shifting trends more efficiently. For investors watching whether BFLY can clear resistance and move toward its target, these signals offer a structured way to monitor momentum without manual chart review.
A move to $11 for Butterfly Network appears ambitious but not unreasonable. The stock trades only about 15% below that level, holds a Strong Buy consensus, and has delivered accelerating revenue with raised guidance and a newly diversified platform strategy. Those are legitimate drivers of further appreciation.
At the same time, the path is not assured. The company remains unprofitable, trades at a valuation that some models consider rich, and must first clear the $10.05 resistance level that has capped recent gains. Investors should monitor quarterly revenue growth, progress toward profitability, commercialization of the Embedded and Garden platforms, and whether the stock can hold above its key support zones. Reaching $11 likely requires continued execution across these fronts rather than sentiment alone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BFLY has been loosely correlated with PACB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BFLY jumps, then PACB could also see price increases.
| Ticker / NAME | Correlation To BFLY | 1D Price Change % | ||
|---|---|---|---|---|
| BFLY | 100% | +2.17% | ||
| PACB - BFLY | 52% Loosely correlated | -2.22% | ||
| QSI - BFLY | 43% Loosely correlated | -0.78% | ||
| CERS - BFLY | 40% Loosely correlated | -1.93% | ||
| INFU - BFLY | 39% Loosely correlated | -2.86% | ||
| NTRA - BFLY | 38% Loosely correlated | -1.23% | ||
More | ||||
| Ticker / NAME | Correlation To BFLY | 1D Price Change % |
|---|---|---|
| BFLY | 100% | +2.17% |
| Health Services category (242 stocks) | 8% Poorly correlated | -0.92% |
| Medical/Nursing Services category (141 stocks) | 8% Poorly correlated | -0.97% |